BioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 95.2% in April

BioAtla, Inc. (NASDAQ:BCAB) saw a significant decline in short interest in April. As of April 15th, there was short interest totaling 113,264 shares, a decline of 95.2% from the March 31st total of 2,365,733 shares. Currently, 7.7% of the shares of the company are short sold. Based on an average daily volume of 68,594 shares, the short-interest ratio is presently 1.7 days.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAtla in a research report on Friday, January 9th. Wall Street Zen upgraded BioAtla to a “hold” rating in a research report on Saturday, April 11th. Finally, Rodman & Renshaw initiated coverage on shares of BioAtla in a research note on Tuesday, January 13th. They set a “buy” rating and a $200.00 target price on the stock. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $200.00.

BioAtla Stock Performance

Shares of BioAtla stock traded down $0.29 during trading hours on Friday, hitting $4.87. The company’s stock had a trading volume of 17,485 shares, compared to its average volume of 49,346. The business has a 50 day moving average price of $7.46 and a two-hundred day moving average price of $23.23. BioAtla has a 12-month low of $3.92 and a 12-month high of $71.50. The company has a market cap of $8.08 million, a PE ratio of -0.10 and a beta of 1.22.

BioAtla (NASDAQ:BCAB) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($8.00) EPS for the quarter, beating the consensus estimate of ($18.00) by $10.00. The business had revenue of $2.00 million during the quarter, compared to analysts’ expectations of $0.70 million.

Institutional Investors Weigh In On BioAtla

Several large investors have recently made changes to their positions in BCAB. Woodline Partners LP bought a new stake in shares of BioAtla in the first quarter worth about $26,000. Acadian Asset Management LLC increased its holdings in shares of BioAtla by 968.9% in the first quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock worth $585,000 after purchasing an additional 1,531,994 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of BioAtla by 9.1% in the third quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock worth $1,339,000 after purchasing an additional 162,647 shares during the last quarter. Millennium Management LLC bought a new stake in shares of BioAtla in the third quarter worth about $235,000. Finally, Susquehanna International Group LLP increased its holdings in shares of BioAtla by 237.6% in the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock worth $174,000 after purchasing an additional 177,760 shares during the last quarter. 77.23% of the stock is owned by institutional investors.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical?stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti?tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.